Navigation Links
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis
Date:11/14/2012

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- TissueGene, Inc. announced today that it has completed patient enrollment for a U.S. Phase II clinical trial of TG-C in patients suffering from severe osteoarthritis of the knee.  TG-C is a therapy that involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 to regenerate cartilage.

The randomized, double-blind, placebo-controlled study has been designed to evaluate the safety and efficacy of TG-C in patients with Grade 3 chronic degenerative joint disease (DJD) of the knee.  This multi-center study has been conducted at five hospitals and clinical research centers across the country specializing in orthopedics.  Patients have received an intra-articular injection of either TG-C or placebo to the damaged joint area.  Patients in this study are being followed for two years with the primary efficacy endpoint analysis being conducted once all patients have reached their one year follow-up.  In conjunction with this milestone, TissueGene's licensing partner, Kolon Life Science, Inc. has completed patient enrollment for a Phase IIb study of TG -C in Korea.  

"We are very pleased with the clinical progress of TG-C in both the US and Korea and look forward to reporting our Phase II data in 2013," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene.

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing novel regenerative therapies for the treatment of various orthopedic diseases.  TissueGene's proprietary technology employs a form of cell-mediated therapy to deliver therapeutic proteins to localized areas of damaged tissue.  The company is currently developing four product candidates for the regeneration of cartilage (TG-C), bone (TG-B), disc (TG-D), and nerve tissue (TG-N).  For more information, please visit http://www.TissueGene.com.

About Kolon Life Science, Inc.

Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary company of Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals.  Its pharmaceutical business division provides active pharmaceutical ingredients and pharmaceutical intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose.  For more information, please visit http://www.kolonls.co.kr.


'/>"/>
SOURCE TissueGene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
4. CryoLife Completes Acquisition of Hemosphere
5. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Ablative Solutions Completes $5.3M Series A Financing
10. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
11. Spine Pain Management, Inc. Completes $500,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):